Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 Jun 24;19(1):620. doi: 10.1186/s12885-019-5831-x.

2.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0. Erratum in: BMC Cancer. 2019 Jun 24;19(1):620.

3.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.

Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.

PMID:
30706247
4.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.

Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA.

Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6.

5.

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD.

Clin Cancer Res. 2016 Aug 1;22(15):3755-63. doi: 10.1158/1078-0432.CCR-15-2499. Epub 2016 Feb 26. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5486.

6.

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA.

J Clin Oncol. 2014 May 10;32(14):1437-44. doi: 10.1200/JCO.2013.52.6590. Epub 2014 Apr 14.

PMID:
24733796
7.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ.

Br J Cancer. 2013 Mar 19;108(5):1052-60. doi: 10.1038/bjc.2013.69. Epub 2013 Feb 19.

8.

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J.

J Psychopharmacol. 2012 Aug;26(8):1071-80. doi: 10.1177/0269881112448946. Epub 2012 Jun 13.

PMID:
22695489
9.

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.

de Haas SL, Zoethout RW, Van Dyck K, De Smet M, Rosen LB, Murphy MG, Gottesdiener KM, Schoemaker RC, Cohen AF, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):282-91. doi: 10.1177/0269881111415731. Epub 2011 Sep 2.

PMID:
21890585
10.

Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects.

de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J.

J Psychopharmacol. 2010 Nov;24(11):1619-29. doi: 10.1177/0269881109106898. Epub 2009 Jul 31.

PMID:
19648220
11.

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.

de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, van Gerven JM.

J Psychopharmacol. 2009 Aug;23(6):625-32. doi: 10.1177/0269881108092595. Epub 2008 Jul 17.

PMID:
18635696
12.

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.

Boot JD, De Haas SL, Van Gerven JM, De Smet M, Leathem T, Wagner J, Denker A, Miller D, Van Doorn MB, Schoemaker RC, Cohen AF, Diamant Z.

Pulm Pharmacol Ther. 2008;21(3):573-7. doi: 10.1016/j.pupt.2008.01.009. Epub 2008 Feb 3.

PMID:
18321743
13.

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.

de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF, van Gerven JM.

J Psychopharmacol. 2008 Jan;22(1):24-32. doi: 10.1177/0269881107082108.

PMID:
18187530
14.

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F.

Nat Med. 2007 Feb;13(2):150-5. Epub 2007 Jan 28.

PMID:
17259994
15.

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM.

J Psychopharmacol. 2007 Jun;21(4):374-83. Epub 2006 Nov 8.

PMID:
17092968
17.

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ.

Cardiovasc Res. 2002 Feb 1;53(2):341-7.

PMID:
11827684

Supplemental Content

Loading ...
Support Center